br Fig A Cell viability
Fig. 7. (A) Cell viability of HeLa and HK-2 Imipenem treated with diﬀerent concentrations of IONs. (B) Viability of HeLa cells treated with diﬀerent samples for 24 h. (C) The tumor volumes and (D) body weight changes of mice in various treatment groups, and (E) the biodistribution of mice injected with MCDION-Se at a dose of 10 mg/kg via the tail vein. (F) Photographs of solid tumor images from diﬀerent treatment groups. (G, H) Pathological analysis of various organs in mice injected with diﬀerent samples via the tail vein. Scale bar: 100 μm.
Conflict of interest
The authors declare no competing financial interest.
Clinical Medicine Grant Support from Shanghai Jiao Tong University School of Medicine (No. shkw2017).
Appendix A. Supplementary data
X. Zeng, L. Mei, TPGS-functionalized polydopamine-modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug re-sistance, Small 13 (2017) 1700623–1700634.
Y. Wang, X. Zhang, K. Zhong, D. Zou, Z. Wu, A tailored nanosheet decorated with A metallized dendrimer for angiography and magnetic resonance imaging-guided
Z. Wu, A multifunctional magnetic composite material as A drug delivery system and A magnetic resonance contrast agent, Part. Part. Syst. Char. 31 (2015) 976–984.
 C. Li, Y. Wang, Y. Du, M. Qian, H. Jiang, J. Wang, N. Murthy, R. Huang, Side eﬀects-avoided theranostics achieved by biodegradable magnetic silica-sealed mesoporous polymer-drug with ultralow leakage, Biomaterials 186 (2018) 1–7.
H. Yang, X. Chen, Simultaneous fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy, Angew. Chem. Int. Ed. 57 (2018) 4902–4906.
J. Lin, Enhanced cisplatin chemotherapy by iron oxide nanocarrier-mediated gen-eration of highly toxic reactive oxygen species, Nano Lett. 17 (2017) 928–937.  C. Fu, H. Zhou, L. Tan, Z. Huang, Q. Wu, X. Ren, J. Ren, X. Meng, Microwave-activated Mn-doped zirconium metal–organic framework nanocubes for highly ef-fective combination of microwave dynamic and thermal therapies against cancer, ACS Nano 12 (2017) 2201–2210.
Contents lists available at ScienceDirect
A phase 1b dose escalation study of ipafricept (OMP\\54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer☆
Kathleen N. Moore a, , Camille C. Gunderson a, Paul Sabbatini b, D. Scott McMeekin a,1, Gina Mantia-Smaldone c, Robert A. Burger d, Mark A. Morgan d, Ann M. Kapoun e, Rainer Karl Brachmann e, Robert Stagg e, Azeez Farooki e, Roisin E. O'Cearbhaill b
a Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK 800 NE 10th Street, OKC, OK 73104, United States of America
b Memorial Sloan Kettering Cancer Center New York, NY and Weill Cornell Medical College, New York, NY, United States of America
c Fox Chase Cancer Center, Philadelphia, PA, United States of America
d University of Pennsylvania, Philadelphia, PA, United States of America
e OncoMed Pharmaceuticals Inc., Redwood City, CA, United States of America
• Wnt signaling in epithelial ovarian cancer is a promising target.
• Ipafricept is a recombinant protein Microtubule organizing center inhibits Wnt signaling.
• Ipafricept, added to paclitaxel and carboplatin was feasible but associated with bone toxicity.
Objectives. The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P).